10 August 2016 - CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes mellitus.

These new drugs are in three classes: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. As part of this project, recommendations from the CADTH Canadian Drug Expert Committee will be developed.

This project is an update to two large projects on pharmacotherapy for type 2 diabetes mellitus completed by CADTH in the past: an evaluation of second- and third-line therapies for type 2 diabtes mellitus originally published in 2010 and an update to this evaluation in 2013.

Read CADTH news article